Stock Track | LivaNova Soars 12.12% on Strong Q1 Results, Raised Guidance, and Positive Sleep Apnea Study Data

Stock Track

07 May

LivaNova PLC (LIVN) shares surged 12.12% in pre-market trading on Wednesday following the release of better-than-expected first-quarter 2025 results, raised full-year guidance, and positive clinical data for its sleep apnea treatment.

The medical technology company reported Q1 revenue of $316.9 million, surpassing the IBES estimate of $302.3 million. Adjusted earnings per share came in at $0.88, significantly beating the expected $0.76. LivaNova's strong performance was driven by high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion.

In light of the robust results, LivaNova raised its full-year 2025 revenue growth guidance to 6.0% to 7.0% on a constant-currency basis, up from the previous range of 5.0% to 6.0%. The company also updated its adjusted diluted earnings per share range to $3.60 to $3.70. Adding to the positive sentiment, LivaNova announced encouraging 12-month data from its OSPREY clinical study for moderate to severe obstructive sleep apnea. The study demonstrated strong response and durability of therapy, with an overall responder rate of 65% and a 68% reduction in both the median Apnea-Hypopnea Index and Oxygen Desaturation Index. These results, coupled with the company's recent premarket approval submission to the FDA for its aura6000 System, suggest potential future growth opportunities in the sleep apnea market for LivaNova.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1153987119"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153987119\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1153987119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153987119","market":"sg","top_or_hot":-1,"title":"Stock Track | LivaNova Soars 12.12% on Strong Q1 Results, Raised Guidance, and Positive Sleep Apnea Study Data","media":"Stock Track","content":"<p>LivaNova PLC (LIVN) shares surged 12.12% in pre-market trading on Wednesday following the release of better-than-expected first-quarter 2025 results, raised full-year guidance, and positive clinical data for its sleep apnea treatment.</p>\n\n<p>The medical technology company reported Q1 revenue of $316.9 million, surpassing the IBES estimate of $302.3 million. Adjusted earnings per share came in at $0.88, significantly beating the expected $0.76. LivaNova's strong performance was driven by high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion.</p>\n\n<p>In light of the robust results, LivaNova raised its full-year 2025 revenue growth guidance to 6.0% to 7.0% on a constant-currency basis, up from the previous range of 5.0% to 6.0%. The company also updated its adjusted diluted earnings per share range to $3.60 to $3.70. Adding to the positive sentiment, LivaNova announced encouraging 12-month data from its OSPREY clinical study for moderate to severe obstructive sleep apnea. The study demonstrated strong response and durability of therapy, with an overall responder rate of 65% and a 68% reduction in both the median Apnea-Hypopnea Index and Oxygen Desaturation Index. These results, coupled with the company's recent premarket approval submission to the FDA for its aura6000 System, suggest potential future growth opportunities in the sleep apnea market for LivaNova.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | LivaNova Soars 12.12% on Strong Q1 Results, Raised Guidance, and Positive Sleep Apnea Study Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | LivaNova Soars 12.12% on Strong Q1 Results, Raised Guidance, and Positive Sleep Apnea Study Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-07 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LivaNova PLC (LIVN) shares surged 12.12% in pre-market trading on Wednesday following the release of better-than-expected first-quarter 2025 results, raised full-year guidance, and positive clinical data for its sleep apnea treatment.</p>\n\n<p>The medical technology company reported Q1 revenue of $316.9 million, surpassing the IBES estimate of $302.3 million. Adjusted earnings per share came in at $0.88, significantly beating the expected $0.76. LivaNova's strong performance was driven by high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion.</p>\n\n<p>In light of the robust results, LivaNova raised its full-year 2025 revenue growth guidance to 6.0% to 7.0% on a constant-currency basis, up from the previous range of 5.0% to 6.0%. The company also updated its adjusted diluted earnings per share range to $3.60 to $3.70. Adding to the positive sentiment, LivaNova announced encouraging 12-month data from its OSPREY clinical study for moderate to severe obstructive sleep apnea. The study demonstrated strong response and durability of therapy, with an overall responder rate of 65% and a 68% reduction in both the median Apnea-Hypopnea Index and Oxygen Desaturation Index. These results, coupled with the company's recent premarket approval submission to the FDA for its aura6000 System, suggest potential future growth opportunities in the sleep apnea market for LivaNova.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1153987119","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153987119","pubTimestamp":1746624954,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"LivaNova PLC  shares surged 12.12% in pre-market trading on Wednesday following the release of better-than-expected first-quarter 2025 results, raised full-year guidance, and positive clinical data for its sleep apnea treatment.In light of the robust results, LivaNova raised its full-year 2025 revenue growth guidance to 6.0% to 7.0% on a constant-currency basis, up from the previous range of 5.0% to 6.0%. The company also updated its adjusted diluted earnings per share range to $3.60 to $3.70. A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"股票赛道LivaNova因强劲的第一季度业绩、上调指引和积极的睡眠呼吸暂停研究数据而飙升12.12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIVN":1},"content_text":"LivaNova PLC (LIVN) shares surged 12.12% in pre-market trading on Wednesday following the release of better-than-expected first-quarter 2025 results, raised full-year guidance, and positive clinical data for its sleep apnea treatment.\nThe medical technology company reported Q1 revenue of $316.9 million, surpassing the IBES estimate of $302.3 million. Adjusted earnings per share came in at $0.88, significantly beating the expected $0.76. LivaNova's strong performance was driven by high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion.\nIn light of the robust results, LivaNova raised its full-year 2025 revenue growth guidance to 6.0% to 7.0% on a constant-currency basis, up from the previous range of 5.0% to 6.0%. The company also updated its adjusted diluted earnings per share range to $3.60 to $3.70. Adding to the positive sentiment, LivaNova announced encouraging 12-month data from its OSPREY clinical study for moderate to severe obstructive sleep apnea. The study demonstrated strong response and durability of therapy, with an overall responder rate of 65% and a 68% reduction in both the median Apnea-Hypopnea Index and Oxygen Desaturation Index. These results, coupled with the company's recent premarket approval submission to the FDA for its aura6000 System, suggest potential future growth opportunities in the sleep apnea market for LivaNova.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}